---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-23-000008"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2023-02-03T23:59:59+00:00"
generated_at: "2026-06-20T00:53:50.731186+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kiora enters private placement ($200K gross) and $10M committed equity line with Lincoln Park Capital

## Summary
- Issued 52,798 shares and 105,596 warrants at $3.788/share for $200K gross proceeds; warrants exercisable at $3.538.
- Committed equity facility allows Kiora to sell up to $10M in common stock to LPC over 36 months at prevailing market prices.
- Proceeds from both agreements to support clinical trials, working capital, and general corporate purposes.
- LPC precluded from short-selling or hedging Kiora's common stock under the Purchase Agreement.
- Kiora may terminate the Purchase Agreement at any time without cost or penalty.

## SEC filing metadata
- accession: 0001372514-23-000008
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2023-02-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000008/0001372514-23-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000008/kprx-20230203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-23-000008
- JSON: https://secwatch.observer/filing/0001372514-23-000008.json
- Plain text: https://secwatch.observer/filing/0001372514-23-000008.txt

## Key facts
- Material Agreements
  KIORA PHARMACEUTICALS INC entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at $10.0 million (effective 2023-02-03).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Lincoln Park Capital Fund, LLC
  - Value: $10.0 million
  - Effective: 2023-02-03
  source text: On February 3, 2023, the Company entered into a purchase agreement (the “Purchase Agreement”) and a registration rights agreement (the “Registration Rights Agreement”), with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up to $10.0 million of Common Stock (subject to certain limitations), from time to time and at the Company’s sole discretion over the term of the Purchase Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000008/0001372514-23-000008-index.htm
- Material Agreements
  KIORA PHARMACEUTICALS INC entered into Securities Purchase Agreement with Lincoln Park Capital Fund, LLC valued at $200,000.00 (effective 2023-02-02).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Lincoln Park Capital Fund, LLC
  - Value: $200,000.00
  - Effective: 2023-02-02
  source text: On February 2, 2023, Kiora Pharmaceuticals, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”), with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which the Company agreed to issue and sell to Lincoln Park, and Lincoln Park agreed to purchase from the Company (i) 52,798 shares (the “Private Placement Shares”) of the Company’s Common Stock, par value $0.01 per share (“Common Stock”) and (ii) warrants (the “Warrants”) to initially purchase an aggregate of up to 105,596 shares of Common Stock (the “Warrant Shares”), at an exercise price of $3.538 per share. The combined purchase price for each Private Placement Share and two Warrants is $3.788, which price represents the “Minimum Price” in accordance with Nasdaq Listing Rule 5635(d), for expected aggregate gross proceeds of $200,000.00.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000008/0001372514-23-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.